Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/26/2024 | $3.00 | Buy | Maxim Group |
7/3/2024 | $4.00 | Buy | H.C. Wainwright |
11/7/2022 | $7.00 | Buy | Lake Street |
Calls for the Immediate Resignation of Four Directors, Including Chairman Peter Staple, Heather Mason, William McKee and Dr. Jeffrey VacircaIntends to Nominate Independent, Qualified Directors at the Company's Next Shareholder Meeting If No Progress is MadeCriticizes Board's Failure to Explain and Recover Damages From Value-Destructive Spectrum Pharmaceuticals AcquisitionUrges Board to Improve its Due Diligence Process Before Any Further M&AThe Buxton Helmsley Group, Inc., a significant shareholder of Assertio Holdings, Inc. (NASDAQ:ASRT), today issued the following letter to the company's Board of Directors.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume AMGN CALL SWEEP BEARISH 07/19/24 $320.00 $27.4K 2.5K 277 LLY CALL TRADE BEARISH 08/16
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024. "Third quarter results reflected solid performance as we continue to establish Rolvedon as our lead asset and drive economic returns from our commercial portfolio," said Brendan O'Grady, Chief Executive Officer. "Rolve
Evidence Corroborates Allegations of Multiple Former Executives Calls on Assertio Board to Release Full Investigation Report and Supporting Materials The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that has inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today responded to the Company's attempt to deny, in its November 11, 2024, press release, the evident product-related fraud at Spectrum Pharmaceuticals, Inc., now wholly-owned by Assertio. "The statement from Assertio this morn
Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O'Grady in response to public comments made November 8, 2024 by a short-seller: To the members of the investment community, As many of you have been awar
10-Q - Assertio Holdings, Inc. (0001808665) (Filer)
8-K - Assertio Holdings, Inc. (0001808665) (Filer)
10-Q - Assertio Holdings, Inc. (0001808665) (Filer)
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024. "Third quarter results reflected solid performance as we continue to establish Rolvedon as our lead asset and drive economic returns from our commercial portfolio," said Brendan O'Grady, Chief Executive Officer. "Rolve
LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release third quarter 2024 financial results on Monday, November 11, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default
Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 Million LAKE FOREST, Ill., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2024. "In my first two months at Assertio, I have been excited to work closely with the team, meet our growing list of oncology clinic customers and focus on ho
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
3 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00
H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of Directors has appointed Brendan P. O'Grady, a highly accomplished pharmaceutical executive, as the Company's new Chief Executive Officer and a member of the board, effective today, May 29, 2024. Mr. O'Grady, a senior healthcare executive with more than 30 years of experience accelerating sales growth and profitability, brings to Assertio a demonstrated understanding of multiple commercial models and a track record of market
LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors. He will serve on the Audit and Compensation committees. Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. His previous experience includes 11 years at Allergan plc, which was acquired by AbbVie, Inc., as Executive Vi
Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company's Chief Executive Officer. The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief exec
Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition